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Aims: Aquaporins (AQPs) are channel proteins that facilitate the rapid passive movement of water. In our studies it
was proved that the decreased AQP5 expression is followed by the increase of uterine contractility. The transient
receptor potential vanilloid 4 (TRPV4) is a calcium channel, which is activated in response to osmotic changes.
Our aim was to determine the possible role of AQP5 in this osmotic regulation of TRPV4, thus in pregnant uterine
contraction.
Main methods: We used RT-PCR and Western blot techniques for the detection of the TRPV4 expression during
pregnancy in rat uterus. The localization of AQP5 and TRPV4 was determined by immunohistochemical studies.
The role of TRPV4 in uterus contraction was investigated in an isolated organ bath system. In vitro uterus con-
tractions were stimulated with KCl and its effect was investigated with the selective TRPV4 agonist (RN1747) and
antagonist (RN1734).
Key ﬁndings: The TRPV4 expression continuously increased from day 18 to the last day of pregnancy. The co-
expression of TRPV4 and AQP5 in the myometrium and endometrium was determined in the late pregnant
uterus. The TRPV4 antagonist and agonist signiﬁcantly decreased and increased uterine contraction, respectively,
especially on the last day of pregnancy.
Signiﬁcance: We presume the decreased AQP5 expression triggers hypertonic stress, which activates TRPV4 and
increases uterus contraction on the day of labor. Based on these ﬁndings, we suppose the TRPV4 effect on uterus
contraction is AQP5 control, which could be a new target in preterm birth therapy.1. Introduction
The signals and mechanisms that synchronize the timing of parturi-
tion are not fully understood and a better understanding of these pro-
cesses would be essential to avert adverse pregnancy outcomes [1]. The
understanding of myometrial contraction at the time of labor is important
for the development of novel therapeutic strategies against preterm
labor, which is the main cause of prenatal mortality and morbidity.
Evidence suggests that myometrial smooth muscle Ca2þ homeostasis
is modulated near the term to promote uterine contractility. In the
myometrium, the entry of extracellular Ca2þ is essential for theDucza), gaspar.robert@med.u-sze
m 13 September 2019; Accepted
is an open access article under tmaintenance of spontaneous rhythmic contractions [2]. The transient
receptor potential vanilloid (TRPV) channels belong to the vanilloid
subfamily of the TRP channel family, a group of nonselective cation
channels permeable to sodium, Ca2þ and magnesium. The TRPV4
channel is a Ca2þ channel activated by a variety of stimuli, including
warm temperature (27–42 C), osmotic changes and endogenous lipids.
The possible inﬂuence of TRPV4 has been reported in the smooth muscle
contraction of pregnant and non-pregnant uterus [3, 4] but its exact role
is still unknown.
Normal water homeostasis in the female reproductive system is
indispensable for healthy pregnancy and successful delivery. Aquaporinsged.hu (R. Gaspar).
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control of pregnant myometrial contractions and cervical ripening [5].
Earlier we identiﬁed AQP1, 2, 3, 5, 8 and 9 in rat uteri on gestational days
18–22. At the end of pregnancy, the expression of AQP5was much higher
as compared with other AQPs, however, its expression dropped
dramatically on the last day of gestation. It was also proved that this type
of water channel is selectively down-regulated by oxytocin [6]. Proges-
terone and progesterone derivatives up-regulated the AQP5 expression,
which was more predominant as compared with estrogen pretreatment.
This ﬁnding was conﬁrmed by hormonally-induced (antigestagen with
prostaglandin E2) preterm labor, resulting in a signiﬁcant drop in the
expression of AQP5 in the rat uterus. The decrease in uterine AQP5
expression during preterm delivery was similar to the normal term uteri,
suggesting that reduced AQP5 expression after progesterone deprivation
may contribute to the initiation of labor [7].
Although this inverse correlation between the AQP5 level and myo-
metrial contraction was found, the mechanism of this phenomenon is still
unknown. We hypothesize an osmotic pathway – through AQP5 – might
have inﬂuence on the changes in TRPV4 function. These osmotic stimuli
for TRPV4 may modify the intracellular Ca2þ level, which results in
myometrial contraction. The aim of our study was to investigate the co-
expression and cooperation of AQP5 and TRPV4 in the pregnant uterus
and their mutual regulatory effect on myometrial contraction.
2. Materials and methods
2.1. Housing and handling of the animals
The animals were treated in accordance with the European Commu-
nities Council Directives (2010/63/EU) and the Hungarian Act for the
Protection of Animals in Research (Article 32 of Act XXVIII). All exper-
iments involving animal subjects were carried out with the approval of
the National Scientiﬁc Ethical Committee on Animal Experimentation
(registration number: IV/198/2013). Sprague–Dawley rats (INNOVO
Ltd., G€od€oll}o, Hungary) were kept at 22 3 C; the relative humidity was
30–70% and the light/dark cycle was 12/12 h. The animals were
maintained on a standard rodent pellet diet (INNOVO Ltd., G€od€oll}o,
Hungary) with tap water available ad libitum. They were sacriﬁced by
CO2 inhalation.
2.2. Mating of the animals
Mature female (180–200 g) and male (240–260 g) Sprague-Dawley
rats were mated in a special mating cage before dawn. Within 4 h after
mating, vaginal smears were taken and a sperm search was performed
under a microscope. If the search proved positive, the female rats were
separated and were regarded as ﬁrst-day pregnant animals.
2.3. RT-PCR studies
2.3.1. Tissue isolation
Rats were terminated by CO2 inhalation, while the fetuses were
terminated by cervical dislocation. The non-pregnant uteri and the
pregnant uterine tissues (from between two implantation places) were
rapidly removed and placed in RNAlater Solution (Sigma-Aldrich,
Hungary). The tissues were frozen in liquid nitrogen and then stored at
-70 C until the extraction of total RNA.
2.3.2. Total RNA preparation from tissue
Total cellular RNA was isolated by extraction with guanidinium
thiocyanate-acid-phenol-chloroform according to the procedure of
Chomczynski and Sacchi [8]. After precipitation with isopropanol, the
RNA was washed with 75% ethanol and then resuspended in diethyl
pyrocarbonate-treated water. RNA purity was controlled at an optical
density of 260/280 nm with BioSpec Nano (Shimadzu, Japan); all sam-
ples exhibited an absorbance ratio in the range of 1.6–2.0. RNA quality2and integrity were assessed by agarose gel electrophoresis.
2.3.3. Real-time quantitative reverse transcription-PCR (RT-PCR)
Reverse transcription and ampliﬁcation of the PCR products were
performed by using the TaqMan RNA-to-CT-Step One Kit (Life Technol-
ogies, Hungary) and an ABI StepOne Real-Time cycler. Reverse-
transcriptase PCR ampliﬁcations were performed as follows: at 48 C
for 15 min and at 95 C for 10 min, followed by 40 cycles at 95 C for 15 s
and at 60 C for 1 min. The generation of speciﬁc PCR products was
conﬁrmed by melting curve analysis. The following primers were used:
assay ID Rn00562837_m1 for the Aqp5 water channel, Rn00576745_m1
for Trpv4 and Rn00667869_m1 for β-actin as endogenous control. All
samples were run in triplicate. The ﬂuorescence intensities of the probes
were plotted against PCR cycle number. The ampliﬁcation cycle dis-
playing the ﬁrst signiﬁcant increase of the ﬂuorescence signal was
deﬁned as the threshold cycle (CT).2.4. Western blot analysis
25 μg of protein per well was subjected to electrophoresis on 4–12%
NuPAGE Bis-Tris Gel in XCell SureLock Mini-Cell Units (Thermo Fisher
Scientiﬁc, Hungary). Proteins were transferred from gels to nitrocellulose
membranes, using the iBlot Gel Transfer System (Thermo Fisher Scien-
tiﬁc, Hungary). The antibody binding was detected with the Western-
Breeze Chromogenic Western blot immunodetection kit (Thermo Fisher
Scientiﬁc, Hungary). The blots were incubated on a shaker with AQP5
(cat. no sc-514022), β-actin (cat. no sc-8432) monoclonal antibody
(Santa Cruz Biotechnology, California, 1:200) and TRPV4 (Thermo
Fisher Scientiﬁc, Hungary, cat. no OSR00136W, 1:200) in the blocking
buffer. Images were captured with the EDAS290 imaging system (Csertex
Ltd., Hungary), and the optical density of each immunoreactive band was
determined with Kodak 1D Images analysis software. Optical densities
were calculated as arbitrary units after local area background
subtraction.2.5. Immunohistochemistry
The localization of TRPV4 and AQP5 in the rat uterus was examined
by immunohistochemistry. Late pregnant (pregnancy days 18 and 22)
uteri were ﬁxed in paraformaldehyde and then embedded in parafﬁn,
sectioned (5-μm-thick tissue sections) deparafﬁnized, rehydrated and
incubated in acidic citrate buffer (pH6) in microwave for antigen re-
covery, then treated with 3% hydrogen peroxide to quench endogenous
peroxidase activity. After washing, sections were placed on normal
blocking solution, treated with rabbit polyclonal anti-TRPV4 (cat. no.
20987-1-AP, Proteintech, UK) and AQP5 (cat. no PA5-36529, Thermo-
Fischer Scientiﬁc, Hungary) primary antibodies in a dilution of 1:200 for
1 h at room temperature. Incubation was performed with the Histo-
Labeling system anti-rabbit secondary antibody conjugated with perox-
idase (Histols Reagent, Hungary) and the reaction was visualized using
3,3-diaminobenzidine tetrachloride (Histols DAB, Histols Reagent,
Hungary). Histological counterstaining was performed with haematox-
ylin. For double immunoﬂuorescence analysis, the Tyramide Signal
Ampliﬁcation Kit (Molecular Probes/ThermoFischer Scientiﬁc, Hungary)
was used with ﬂuorescent-labeled tyramide (Alexa Fluor 594-labeled,
cat. no. T20925, Invitrogen, 1:100) to detect color red and directly
labeled secondary antibody (Alexa Fluor 488 goat anti-rabbit, Invitrogen,
1:200) to detect color green. Micrographs were generated using an
Olympus Fluoview-1000 system on an Olympus IX81 microscope stage
equipped with an Olympus DP70 digital camera and through an Olympus
UPlan FL N, Phase2 objective. The scale bar represents 50 μm. The
counting of TRPV4 and aquaporin positive myometrial cells was per-
formed in 3 different standardized areas from each slides, using ImageJ
software.
Fig. 1. The changes in mRNA (A) and protein expression (B) of TRPV4 in the non-pregnant uterus (estrus phase) and on different gestational days in pregnant rat uteri
(n ¼ 6 on investigated days of pregnancy). Correlation between TRPV4 and AQP5 mRNA (C) and protein (D) expression from pregnancy day 18 to day 22 in uterus.
Original uncropped gel images can be viewed in Supplementary Fig. 1. NP: non-pregnant, ns > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001; compared to the pre-
vious day.
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D'Agostino-Pearson omnibus test was performed to determine the
normal distribution of the data. One-way ANOVA followed by Bonfer-
roni's post hoc test was used for statistical analysis of the immuno-
chemistry. A value of p < 0.05 was considered statistically signiﬁcant.2.6. Isolated organ bath study
Uteriwere removed fromrats onday18or 22of pregnancy. 5-mm-long
muscle rings were sliced from the uterine horns andmounted vertically in
an organ bath containing 10 ml de Jongh solution (composition: 137 mM
NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 4 mM3NaH2PO4, 6 mM glucose, pH¼ 7.4). The organ bathwasmaintained at 37
C and carbogen (95% O2 þ 5% CO2) was bubbled through it. After
mounting, the rings were equilibrated for about 1 h before experiments
were undertaken; with a solution change every 15 min.
2.6.1. Contractility studies
In the isolated uterine tissue rings, rhythmic contractions were
induced with 25mM KCl solution. Without washing out the contractile
agent, the effects of a TRPV4 antagonist (RN1734, Sigma-Aldrich,
Hungary) and a TRPV4 agonist (RM1747, Sigma-Aldrich, Hungary)
were tested on the uterine contractions in the concentration range of 3
 108-105M in a cumulative manner. Control uteri were treated
E. Ducza et al. Heliyon 5 (2019) e02697with the solvent of the compounds. Recording was performed at each
concentration of the examined agents for 5 min. The tension of the
myometrial rings was measured with a strain gauge transducer (SG-02;
MDE Ltd., Budapest, Hungary) and contractions were recorded and
later analyzed with the SPEL Advanced ISOSYS Data Acquisition Sys-
tem (MDE Ltd., Budapest, Hungary). The effects of RN1734 and
RN1747 were expressed as the percentage of the area under curve
(AUC) of KCl induced contractions. The dose-response curves were
ﬁtted and the statistical analysis of EC50 and Emax values was
performed.2.7. Statistical analyses
All experiments were carried out on at least 6 animals, repeated
3 times, and each value is given as a mean  S.E.M. All curve ﬁt-
tings, data calculations and statistical analyses were performed with
Prism 5.0 computer software (Graph Pad Software Inc, San Diego,A.
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Fig. 2. Representative pictures showing expressions of the AQP5 (A) and TRPV4 (B) a
n ¼ 6, ns > 0.05, compared to the previous day.
4CA, USA). The curves were generated by ﬁtting the data with an
equation using the Graphpad Prism software (Y¼Bottom þ (Top-
Bottom)/(1 þ 10^((LogEC50-X))), where x ¼ log (concentration).
Comparisons were made by one-way ANOVA tests with the Tukey
posttest or two-tailed unpaired t-test.
3. Results
TRPV4 mRNA and protein expression were determined in the non-
pregnant and pregnant rat uteri (Fig. 1A and B). The changes in the
mRNA and protein level showed correlation on the investigated day. The
lowest expression was measured on pregnancy day 18 and it continu-
ously increased towards the day of labor. Strong correlation was found
between the AQP5 [6] and the TRPV4 mRNA expression from pregnancy
day 18–22 (r2 ¼ 0.9577) (Fig. 1C) and moderate correlation in the pro-
tein expression between AQP5 and TRPV4 (r2 ¼ 0.6452) (Fig. 1D).
Based on the summarized immunohistochemical studies, weB.
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Fig. 3. Representative pictures showing expressions of the AQP5 (A) and TRPV4 (B) and these co-expressions (C) in the endometrium on days 18 and 22 of pregnancy.
n ¼ 6,*p < 0.05, ***p < 0.001 compared to the previous day.
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the uterus tissue. The changes of the myometrial expression of AQP5 and
TRPV4 were not signiﬁcant on pregnancy day 18 and day 22 (Fig. 2). The
endometrial expressions of both of investigated proteins were signiﬁ-
cantly higher than in myometrium. The number of AQP5 immunpositive
cells were signiﬁcantly lower on the last day of pregnancy (Fig. 3D) in
contrast the number of TRPV4 immunopositive cells were higher on day
22 (Fig. 3E). The endometrial andmyometrial co-expression of AQP5 and
TRPV4 was proved on both investigated days of late pregnancy (Figs. 2C
and 3C).
The uterine contraction inﬂuencing effects of TRPV4 agonist and
antagonist were investigated in an isolated organ bath system (Fig. 4.).
The agonist (RN1747) had a slight relaxing effect on day 18 (9.93%) in
105 M concentration. The antagonist (RN1734) had a signiﬁcant
relaxing effect (30.33 %) on the same day and in the same concentration
(Fig. 4A).
The agonist had no effect on uterus relaxation (-16.87%), whereas it
induced uterus contraction on pregnancy day 22. The antagonist had a
pronounced relaxing effect (44.52%) on the last of pregnancy (Fig. 4B).54. Discussion
The exact mechanisms of preterm delivery, which can be associated
with immediate and long-term neonatal complications, are largely un-
known [9]. The management of preterm birth involves the identiﬁcation
of the factors which induced the untimely uterine contraction [10]. In
our study we looked for new mechanisms through which uterine
contraction is adjustable.
The normal homeostasis of water in the female reproductive system is
indispensable for healthy pregnancy and successful birth. AQPs are
present during parturition, participating in the control of pregnant
myometrial contractions and cervical ripening [5]. Based on earlier
studies, we know that the expression of AQP5 is dominant during preg-
nancy and this expression dramatically decreases on the last day of
gestation in rat. It was also proved that this type of water channel is
selectively down-regulated by oxytocin, which stimulated uterus con-
tractions [6], and the uterus relaxing progesterone and progesterone
derivatives up-regulated the AQP5 expression [7]. Based on these ﬁnd-
ings, we conﬁrmed an inverse correlation between the AQP5 level and
myometrial contractions. We hypothesize that a low AQP5 level may
induce or increase the late pregnant myometrium contractility. The key
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Fig. 4. Effect of selective TRPV4 agonist (RN1747) and antagonist (RN1734) on KCl-evoked control contraction of rat uteri on days 18 (A) and 22 (B) of gestation. The
statistical analyses were carried out with the two-tailed unpaired t-test. Each value denotes the mean  S.E.M, n ¼ 6. *p < 0.05; ***p < 0.001.
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especially at the time of delivery. We suppose an osmotic pathway in this
regulatorymechanism in the pregnant uterus. We investigated pregnancy
days 18 and 22 with special attention because the changes of AQP5 and
TRPV4 expression were the most signiﬁcant in rat.
TRPV channels are expressed in the male and female reproductive
tissues and play a crucial regulatory role in various physiological actions.
The expression of TRPV4mRNAwas observed in rat prostatic tissue [11].
They are responsible for oocyte maturation and activation and for
fertilization [12]. TRPV1 is present in the human placenta and the
deregulation in TRPV1 expression was found in preeclampsia [13].
TRPV6 expression was proved during pregnancy in the bovine uterine
endometrium and placenta [14].
The TRPV4 channel is a Ca2þ channel, which is activated by osmotic
changes. This channel is widely expressed in the smooth muscle of the
cardiovascular [15], digestive [16, 17], respiratory [18] and reproduc-
tive system [11]. Current evidence suggests that myometrial smooth
muscle Ca2þ homeostasis is modulated near term to promote uterine
contractility. In the human myometrium, the entry of extracellular Ca2þ
is essential for the maintenance of spontaneous rhythmic contractions
[19].
It is supported by much evidence that the AQP5 water channel is an
interacting partner of the TRPV4 channel in the smooth muscles of the
airway system [20] and the gastrointestinal tract [21]. Aure et al. [21]
recognized the functional connection between AQP5 and TRPV4 in6salivary glands, other studies proved that the hypotonic reduction of
AQP5 expression requires the TRPV4 function, furthermore it is essential
for the mechanism of regulatory volume decrease in salivary gland cells
[22, 23].
We determined the dynamic changes of TRPV4 expression during
pregnancy in rat uterus. Based on literature data, this alteration of TRPV4
expression in the uterus seems to be sex hormone-dependent, mostly
depending on progesterone (P4) effect. P4 analogue, levonorgestrel
could down regulate the expression of TRPV4 to reduce the ciliary beat
frequency in both humans and mice, suggesting the possible mechanism
of tubal pregnancy [24]. P4 reduces TRPV4 expression in human tracheal
and mammary gland ductal epithelial cell lines [25]. Decreased TRPV4
expression and promoter activity were also observed in the presence of
P4 in human aortic vascular smooth muscle cells [25]. This is consistent
with our results because the level of P4 decreases at the end of pregnancy
[26], which increases TRPV4 expression. It is known from our previous
results that AQP5 expression is up-regulated by P4 [7]. We suppose a
potential hormone regulated cooperation between the AQP5 and TRPV4
expression.
We found an inverse correlation between the AQP5 and TRPV4
mRNA and protein expression. The putative cooperation between AQP5
and TRPV4 was revealed by our immunohistochemical ﬁndings. We have
conﬁrmed the changes in the AQP5 and TRPV4 expressions in the uterus
and the co-expression of these proteins at the end of pregnancy. Similar
co-expression and functional connection were found in the central
E. Ducza et al. Heliyon 5 (2019) e02697nervous system. Astrocytes possess a TRPV4/AQP4 complex, which is an
essential component in the brain's volume homeostasis [27].
Strategies designed to modulate the entry of extracellular Ca2þ into
smooth muscle cells, and thereby uterus contractility, have been less than
successful in preventing or halting the progression of preterm labor thus
far [28]. The changes in the intracellular concentration of free Ca2þ in-
ﬂuence muscle contraction, hormone secretion, gene expression, cell
proliferation, and many other critical processes [29]. Current evidence
suggests that myometrial smooth muscle cell Ca2þ homeostasis is
modulated near term to promote uterine contractility. TRPV4, which is
the osmotic calcium channel, might have a role in myometrial contrac-
tility and Ca2þ signaling. Earlier the functional role of TRPV4 in modu-
lating myometrial contractility was investigated in murine model by
HC067074 (TRPV4 antagonist), which prolonged pregnancy [4]. We
determined the effect of the TRPV4 channel in the regulation of late
pregnant rat uterus contraction with TRPV4 agonist and antagonist. The
TRPV4 agonist had a negligible relaxing effect on uterine contraction on
day 18 at the highest concentration. In contrast, a contraction-inducing
effect was measured on the last day of pregnancy.
RN-1734, the antagonist which was used in our studies, completely
inhibits both ligand-induced and hypotonicity-induced activation of
TRPV4, without affecting the activity of other TRP channels [30]. The
agonist RN-1747 is mostly selective for TRPV4 although low level acti-
vation of TRPV1 became apparent at high (100 μM) concentration and
antagonism of TRPM8 was observed, too [31]. We proved the relaxing
effect of RN-1734 on both of the investigated pregnancy days, with the
major effect on the last day of rat pregnancy. We presume it can be
explained by the increased expression of TRPV4 and the decreased
expression of AQP5. In non-pregnant and pregnant mouse uterus another
TRPV4 antagonist (HC067047) also inhibited contraction induced by
PGF2α (3). There is no way to investigate the physiological role of AQP5
in the myometrial contraction because of the lack of non-toxic tissue- and
subtype-selective agonists or antagonists.
Based on our ﬁndings we presume the decreased AQP5 expression
triggers an osmotic stress, which activates TRPV4 and increases uterus
contraction on the day of labor. This phenomenon can conﬁrm the future
role of TRPV4 antagonist in the tocolytic therapy.
5. Conclusion
Nowadays, we do not have exact information on the initiation step of
labor. The therapy of preterm birth is an unresolved problem; therefore
we were looking for new targets for the tocolytic therapy. The dynamic
change of AQP5 expression was proved during pregnancy with the
negative correlation between the AQP5 expression and myometrial
contraction. First, we determined the co-expression of the osmotic active
Ca2þ-channel, TRPV4 and AQP5 in pregnant myometrial and endome-
trial tissues. The demonstration of TRPV4 antagonists in the uterine
relaxation effect, on the day of birth, can be the new pathway in inﬂu-
encing myometrial contractility.
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